$NWBO News

Northwest Biotherapeutics Announces Expansion of Its Technical Team

Northwest Biotherapeutics Announces NHSBT Collaboration to Support DCVax-L Production in the UK

Northwest Biotherapeutics and the UK National Health Service Blood and Transplant Announce Collaboration to Support DCVax®-L Production

Northwest Biotherapeutics Highlights Personalized Cancer Vaccine Approach at NHS Oncology Conference

Northwest Biotherapeutics Announces Keynote Presentation on Harnessing Immunity: A Personalized, Multi-Target Approach to Cancer At the UK National Health Service Annual Oncology Conference

Northwest Biotherapeutics Announces MOU for Collaboration With the Saudi Pharmaceutical Industries and Medical Appliance Company

Northwest Biotherapeutics Presents Updated Survival Data from Phase III Trial of DCVax®-L For Glioblastoma Using Individual Patient Level Data in Multiple Independent Analyses

Northwest Biotherapeutics Announces Scientific Presentation on Propensity Score Matching at the British Neuro-Oncology Society Annual Meeting

Northwest Biotherapeutics Appoints Dr. Annalisa Jenkins As Strategic Adviser To Advance Dendritic Cell Cancer Vaccine Platform

Northwest Biotherapeutics Announces Establishment Of the Company's Own Dedicated Leukapheresis Clinic

Northwest Biotherapeutics Announces That Construction Activities Are Under Way For the First Grade C Manufacturing Suite in the Sawston, UK Facility

Northwest Biotherapeutics: Q3 Earnings Snapshot

Northwest Biotherapeutics Announces That Its Acquisition of Advent BioServices Ltd. Has Closed

Northwest Biotherapeutics Announces Agreement to Acquire Advent BioServices Ltd.

Northwest Biotherapeutics Announces the Passing of Its Senior Vice President and General Counsel, Mr. Les Goldman

Northwest Biotherapeutics: Q2 Earnings Snapshot

Northwest Biotherapeutics Announces Upcoming Presentation On Next Generation Dendritic Cells for Enhanced Anti-Tumor Treatments

Northwest Biotherapeutics: Q1 Earnings Snapshot

Northwest Biotherapeutics: A Spike On Their Expected Imminent Approval

Northwest Biotherapeutics: All Is Not Well With This One